Yichen Wang

Yichen Wang

Auto-generated profile, based on publicly available information

Yichen Wang

Wellcome Sanger Institute

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2021 in Nature
Verified
Journal Article
Closed access
PDF file
FAFederico Abascal
Federico Abascal
LHLuke M. R. Harvey
Luke M. R. Harvey
EMEmily Mitchell
Emily Mitchell
ALAndrew R. J. Lawson
Andrew R. J. Lawson
SLStefanie V. Lensing
Stefanie V. Lensing
IMIñigo Martincorena
Iñigo Martincorena

19 March 2025 in Nature
Verified
Journal Article
Open access
PDF file
TCTim H. H. Coorens
Tim H. H. Coorens
GCGrace Collord
Grace Collord
HJHyungchul Jung
Hyungchul Jung
YWYichen Wang
Yichen Wang
LMLuiza Moore
Luiza Moore
MSMichael R. Stratton
Michael R. Stratton
The landscapes of somatic mutation in normal cells inform us about the processes of mutation and selection operative throughout life, providing insight into normal ageing and the earliest stages of cancer development1. Here, by whole-genome sequencing of 238 microdissections2 from 30 individuals, including 18 with gastric cancer, we elucidate the developmental trajectories of normal and malignant gastric epithelium. We find that gastric glands are units of monoclonal cell populations that accrue roughly 28 somatic single-nucleotide variants per year, predominantly attributable to endogenous mutational processes. In individuals with gastric cancer, metaplastic glands often show elevated mutation burdens due to acceleration of mutational processes linked to proliferation and oxidative damage. Unusually for normal cells, gastric epithelial cells often carry recurrent trisomies of specific chromosomes, which are highly enriched in a subset of individuals. Surveying 829 polyclonal gastric microbiopsies by targeted sequencing, we find somatic ‘driver’ mutations in a distinctive repertoire of known cancer genes, including ARID1A, ARID1B, ARID2, CTNNB1 and KDM6A. The prevalence of mutant clones increases with age to occupy roughly 8% of the gastric epithelial lining by age 60 years and is significantly increased by the presence of severe chronic inflammation. Our findings provide insights into intrinsic and extrinsic influences on somatic evolution in the gastric epithelium in healthy, precancerous and malignant states.

26 January 2023 in Nature Genetics
Verified
Journal Article
Open access
PDF file
YWYichen Wang
Yichen Wang
PRPhilip S. Robinson
Philip S. Robinson
TCTim H. H. Coorens
Tim H. H. Coorens
LMLuiza Moore
Luiza Moore
HLHenry Lee-Six
Henry Lee-Six
MSMichael R. Stratton
Michael R. Stratton
APOBEC mutational signatures SBS2 and SBS13 are common in many human cancer types. However, there is an incomplete understanding of its stimulus, when it occurs in the progression from normal to cancer cell and the APOBEC enzymes responsible. Here we whole-genome sequenced 342 microdissected normal epithelial crypts from the small intestines of 39 individuals and found that SBS2/SBS13 mutations were present in 17% of crypts, more frequent than most other normal tissues. Crypts with SBS2/SBS13 often had immediate crypt neighbors without SBS2/SBS13, suggesting that the underlying cause of SBS2/SBS13 is cell-intrinsic. APOBEC mutagenesis occurred in an episodic manner throughout the human lifespan, including in young children. APOBEC1 mRNA levels were very high in the small intestine epithelium, but low in the large intestine epithelium and other tissues. The results suggest that the high levels of SBS2/SBS13 in the small intestine are collateral damage from APOBEC1 fulfilling its physiological function of editing APOB mRNA.

29 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
HLHenry Lee-Six
Henry Lee-Six
TTTaryn D. Treger
Taryn D. Treger
MDManas Dave
Manas Dave
TCTim Hh Coorens
Tim Hh Coorens
NANathaniel D. Anderson
Nathaniel D. Anderson
SBSam Behjati
Sam Behjati
A paradigm of childhood cancers is that they have a low mutation burden, with some ostensibly bearing fewer mutations than the normal tissues from which they derive. We set out to resolve this paradox by examining paediatric renal cancers with exceptionally few mutations using high resolution, high depth sequencing approaches. We find that apparent hypomutation is the result of unusual clonal architecture due to a normal tissue-like mode of tumour evolution, raising the possibility that the mutation burden of some cancers has been systematically misjudged.

9 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
YWYichen Wang
Yichen Wang
WKWilliam Knight
William Knight
AFAida Ferreiro-Iglesias
Aida Ferreiro-Iglesias
BABehnoush Abedi-Ardekani
Behnoush Abedi-Ardekani
MPMy H. Pham
My H. Pham
MSMichael R. Stratton
Michael R. Stratton
Lifestyle, environmental and other exposures to exogenous mutagens generate somatic mutations in normal human cells in vivo and increase cancer risk. However, the global repertoire of exogenous mutagen exposures is uncertain. The mutational signatures of mutagens in normal tissues offer opportunities to detect such exposures and survey them at population level. Using single-molecule duplex sequencing of normal kidney (n=319) and blood (n=272) samples from 10 countries, we show that normal kidney cell genomes report an extensive repertoire of somatic mutational signatures. Microdissection of kidney structures revealed that proximal tubules exhibit higher mutation rates than other components of the nephron and most normal cell types despite low cell division rates. This is explained by marked enrichment of mutational signatures due to known exogenous carcinogenic mutagens including the plant-derived aristolochic acids, as well as several signatures of unknown causes including an unknown agent prevalent in Japan (SBS12), and signatures of uncertain origins (SBS40b and SBS40c). The results suggest the existence of multiple, common, systemically circulating mutagens affecting human populations and indicate that the genomes of kidney proximal tubule cells report such exposures with high sensitivity.

22 May 2025 in Research Square
Verified
Preprint
Open access
PDF file
MSMichael Stratton
Michael Stratton
SLSum Yee Yee Leung
Sum Yee Yee Leung
YWYichen Wang
Yichen Wang
PRPhilip Robinson
Philip Robinson
LTLaura Thomas
Laura Thomas
PCPeter Campbell
Peter Campbell
The succession of somatic genetic events associated with the conversion of a normal colorectal epithelial cell into a colorectal carcinoma constitutes a paradigmatic model of cancer development. Familial Adenomatous Polyposis (FAP) is caused by constitutional inactivating mutations in APC, the central gatekeeper gene of colorectal cancer, and is associated with a substantially increased lifetime-risk of colorectal cancer. To investigate the earliest stages of neoplastic change due to APC inactivation, we microdissected and individually whole genome sequenced 279 histologically normal and abnormal colorectal crypts from 15 individuals with FAP. Histologically normal crypts generally exhibited similar mutation burdens and mutational signatures to normal crypts from wild-type individuals of the same age, with 1/110 carrying a somatic inactivating APC mutation. By contrast, 9/18 aberrant crypt foci carried somatic APC mutations and exhibited modestly increased burdens of some mutational signatures found in normal crypts. 12/13 diminutive adenomatous polyps (< 5mm diameter) showed somatic APC mutations and carried substantially increased mutation loads of most mutational signatures present in normal crypts. Phylogenetic trees of crypts from aberrant crypt foci and adenomatous polyps revealed that some had acquired their initiating somatic APC mutations decades previously during the first few years of life. The results catalogue the changes in somatic mutation rates, mutational processes and “driver” mutations in cancer genes during the earliest stages of colorectal neoplastic transformation initiated by APC inactivation and highlight the long periods of clonal evolution required for a cancer to develop.